Link to this page
Physician Data Query
| Preferred Name | temozolomide | |
| Synonyms |
M and B 39831 Temomedac imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- SCH 52365 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one RP-46161 Temodal 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide TMZ M & B 39831 Temodar CCRG-81045 Temcad |
|
| Definitions |
A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1244" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1244" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041671 |
|
| altLabel |
M and B 39831 Temomedac imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- SCH 52365 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one RP-46161 Temodal 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide TMZ M & B 39831 Temodar CCRG-81045 Temcad
|
|
| CAS Registry |
85622-93-1
|
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000038502 http://purl.bioontology.org/ontology/PDQ/CDR0000355821 http://purl.bioontology.org/ontology/PDQ/CDR0000037984 http://purl.bioontology.org/ontology/PDQ/CDR0000038464 http://purl.bioontology.org/ontology/PDQ/CDR0000352306 http://purl.bioontology.org/ontology/PDQ/CDR0000037975 http://purl.bioontology.org/ontology/PDQ/CDR0000433523 http://purl.bioontology.org/ontology/PDQ/CDR0000257908 http://purl.bioontology.org/ontology/PDQ/CDR0000442408 http://purl.bioontology.org/ontology/PDQ/CDR0000433525 http://purl.bioontology.org/ontology/PDQ/CDR0000301904 http://purl.bioontology.org/ontology/PDQ/CDR0000038026 http://purl.bioontology.org/ontology/PDQ/CDR0000433522 http://purl.bioontology.org/ontology/PDQ/CDR0000038450 http://purl.bioontology.org/ontology/PDQ/CDR0000038492 http://purl.bioontology.org/ontology/PDQ/CDR0000372896 http://purl.bioontology.org/ontology/PDQ/CDR0000405846 http://purl.bioontology.org/ontology/PDQ/CDR0000043341 http://purl.bioontology.org/ontology/PDQ/CDR0000429561 http://purl.bioontology.org/ontology/PDQ/CDR0000375023 http://purl.bioontology.org/ontology/PDQ/CDR0000405845 http://purl.bioontology.org/ontology/PDQ/CDR0000043450 http://purl.bioontology.org/ontology/PDQ/CDR0000361541 http://purl.bioontology.org/ontology/PDQ/CDR0000038068 http://purl.bioontology.org/ontology/PDQ/CDR0000038606 http://purl.bioontology.org/ontology/PDQ/CDR0000340966 http://purl.bioontology.org/ontology/PDQ/CDR0000445605 http://purl.bioontology.org/ontology/PDQ/CDR0000037788 http://purl.bioontology.org/ontology/PDQ/CDR0000042228 http://purl.bioontology.org/ontology/PDQ/CDR0000371721 http://purl.bioontology.org/ontology/PDQ/CDR0000038000 http://purl.bioontology.org/ontology/PDQ/CDR0000405999 http://purl.bioontology.org/ontology/PDQ/CDR0000257909 |
|
| cui |
C0126551 C0701506 C1524087 C0076080 C4087085 C0108742 C4082706 C4287817 C0876179
|
|
| Date last modified |
2016-02-22
|
|
| definition |
A triazene analog of dacarbazine with antineoplastic activity. As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1244" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1244" NCI Thesaurus)
|
|
| IND Code |
42084
|
|
| Legacy PDQ ID |
4834
|
|
| LT |
TRD
|
|
| NCI ID |
C1244
|
|
| notation |
CDR0000041671
|
|
| NSC Code |
362856
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
temozolomide
|
|
| tui |
T109 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |